Overcoming clinical BCR-ABL1 compound mutant resistance with combined ponatinib and asciminib therapy.

ABSTRACT: BCR-ABL1 compound mutations can lead to resistance to ABL1 inhibitors in chronic myeloid leukemia (CML), which could be targeted by combining the ATP-site inhibitor ponatinib and the allosteric inhibitor asciminib. Here, we report the clinical validation of this approach in a CML patient, providing a basis for combination therapy to overcome such resistance.

SUBMITTER: Eide CA 

PROVIDER: S-EPMC11771825 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature